Trader consensus prices a near-certain delay for Encore Medical’s IPO, with the “no IPO before June 2026” outcome at 100.0% market-implied odds. The company filed its S-1 in September 2025 seeking to raise roughly $15 million at $5 per share on NYSE American to fund FDA clinical trials for its transcatheter cardiac implants, yet no pricing, roadshow, or first-day close has occurred despite earlier target dates around April 2026. Persistent pre-revenue status, ongoing trial requirements, and subdued med-tech IPO activity have kept the process stalled. Any acceleration would require rapid FDA milestones, favorable equity-market conditions for small-cap healthcare listings, or revised offering terms that restore underwriter momentum before the June resolution window closes.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডEncore Medical IPO Closing Market Cap
Encore Medical IPO Closing Market Cap
No IPO before June 2026 100.0%
<45M <1%
45M–50M <1%
50M–55M <1%
$31,504 Vol.
$31,504 Vol.
Apr 22, 2026
<45M
No
45M–50M
No
50M–55M
No
55M+
No
No IPO before June 2026
Yes
No IPO before June 2026 100.0%
<45M <1%
45M–50M <1%
50M–55M <1%
$31,504 Vol.
$31,504 Vol.
Apr 22, 2026
<45M
$7,905 Vol.
No
45M–50M
$4,685 Vol.
No
50M–55M
$2,192 Vol.
No
55M+
$4,427 Vol.
No
No IPO before June 2026
$12,296 Vol.
Yes
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus prices a near-certain delay for Encore Medical’s IPO, with the “no IPO before June 2026” outcome at 100.0% market-implied odds. The company filed its S-1 in September 2025 seeking to raise roughly $15 million at $5 per share on NYSE American to fund FDA clinical trials for its transcatheter cardiac implants, yet no pricing, roadshow, or first-day close has occurred despite earlier target dates around April 2026. Persistent pre-revenue status, ongoing trial requirements, and subdued med-tech IPO activity have kept the process stalled. Any acceleration would require rapid FDA milestones, favorable equity-market conditions for small-cap healthcare listings, or revised offering terms that restore underwriter momentum before the June resolution window closes.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
মার্কেট ওপেন হয়েছে: Apr 3, 2026, 7:59 PM ET
ভলিউম
$31,504শেষ তারিখ
Apr 22, 2026মার্কেট ওপেন হয়েছে
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...ফলাফল প্রস্তাবিত: No
কোনো ডিসপিউট নেই
চূড়ান্ত ফলাফল: No
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus prices a near-certain delay for Encore Medical’s IPO, with the “no IPO before June 2026” outcome at 100.0% market-implied odds. The company filed its S-1 in September 2025 seeking to raise roughly $15 million at $5 per share on NYSE American to fund FDA clinical trials for its transcatheter cardiac implants, yet no pricing, roadshow, or first-day close has occurred despite earlier target dates around April 2026. Persistent pre-revenue status, ongoing trial requirements, and subdued med-tech IPO activity have kept the process stalled. Any acceleration would require rapid FDA milestones, favorable equity-market conditions for small-cap healthcare listings, or revised offering terms that restore underwriter momentum before the June resolution window closes.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ভলিউম
$31,504শেষ তারিখ
Apr 22, 2026মার্কেট ওপেন হয়েছে
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...ফলাফল প্রস্তাবিত: No
কোনো ডিসপিউট নেই
চূড়ান্ত ফলাফল: No
Trader consensus prices a near-certain delay for Encore Medical’s IPO, with the “no IPO before June 2026” outcome at 100.0% market-implied odds. The company filed its S-1 in September 2025 seeking to raise roughly $15 million at $5 per share on NYSE American to fund FDA clinical trials for its transcatheter cardiac implants, yet no pricing, roadshow, or first-day close has occurred despite earlier target dates around April 2026. Persistent pre-revenue status, ongoing trial requirements, and subdued med-tech IPO activity have kept the process stalled. Any acceleration would require rapid FDA milestones, favorable equity-market conditions for small-cap healthcare listings, or revised offering terms that restore underwriter momentum before the June resolution window closes.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা